Humand | $66,000,000 | (Feb 24, 2026)
Solid (AI for Data) | $20,000,000 | (Feb 24, 2026)
Comeryx | $7,500,000 | (Feb 24, 2026)
Certified by Founder
Lodge
Indapta Therapeutics
start up
United States
- Seattle & Houston
- 18/12/2024
- Unknown
- $22,500,000
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
- Industry Biotechnology
- Website https://indapta.com/
- LinkedIn https://www.linkedin.com/company/indapta-therapuetics/
Maazah | $2,000,000 | (Feb 24, 2026)
Turgo.ai | $1,000,000 | (Feb 24, 2026)
Sherpas | $3,200,000 | (Feb 24, 2026)
Patientdesk.ai (YC W26) | $1,000,000 | (Feb 24, 2026)
Aalyria | $100,000,000 | (Feb 24, 2026)
Ubicquia, Inc | $106,000,000 | (Feb 24, 2026)
Freeform | $67,000,000 | (Feb 24, 2026)
Coral Care | $13,000,000 | (Feb 24, 2026)
Reload | $2,275,000 | (Feb 24, 2026)